Abstract
Fibroblast growth factor 23 (FGF23), a known regulator of phosphate homeostasis, is produced by cells residing in bone, namely, osteocytes, to target a distant organ, the kidney. Elevated FGF23 levels have recently been found systemically and in osteocytes in patients and animal models of chronic kidney disease. Associations between serum FGF23 level and vascular dysfunction, vascular calcification, and increased risk of cardiovascular disease have also been observed. In this review we discuss FGF23 expression in osteocytes and the potential means to regulate expression and function of this protein at the osteocyte level.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Bone Remodeling*
-
Bone and Bones / metabolism*
-
Bone and Bones / physiopathology
-
Fibroblast Growth Factor-23
-
Fibroblast Growth Factors / metabolism*
-
Homeostasis
-
Humans
-
Kidney / metabolism
-
Kidney / physiopathology
-
Osteocytes / metabolism*
-
Phosphates / metabolism
-
Renal Insufficiency, Chronic / metabolism
-
Renal Insufficiency, Chronic / physiopathology
-
Renal Insufficiency, Chronic / therapy
-
Signal Transduction
-
Vascular Calcification / metabolism
-
Vascular Calcification / physiopathology
-
Vascular Calcification / therapy
Substances
-
FGF23 protein, human
-
Phosphates
-
Fibroblast Growth Factors
-
Fibroblast Growth Factor-23